Research Article A comparative evaluation of efficacy and safety of daily dosing versus alternate day dosing of Rosuvastatin for dyslipidemic

Background: Cardiovascular disease (CVD) is the most common contributor of morbidity and mortality in underdeveloped and developing countries and places a huge burden on the society in terms of health care resources and loss of productivity. Statins are the most popular hypolipidemic drug used to treat hyperlipidemia which is generally administered daily. Objectives: The study was conducted to compare the percent change of LDL-C, TC, TG and HDL and compare the safety of Rosuvastatin in patients of dyslipidemia. Material and Methods: Sixty patients were randomly divided into two groups: once daily group and Alternate day group of rosuvastatin 10mg for six weeks. The lipid profile was compared from the baseline and at end of six weeks. Results: Baseline characters of both the groups were well balanced. LDL-C was reduced by 23.8 % in once-daily group and 26.05 % in alternate-day group, respectively. Changes were also recorded for the other lipid parameters (TC, TG, HDL). Such changes were found to be of no significant difference when compared between the two groups (p>0.05 NS) Conclusion: Alternate day therapy is as effective as the once -daily dosing with rosuvastatin in Indian population in improving the lipid parameters in dyslipidemic patients.